Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data

The outcomes of a successful pre-NDA meeting with the FDA are: As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and ...